Wiley Bros. Aintree Capital, LLC Biogen Inc. Transaction History
Wiley Bros. Aintree Capital, LLC
- $5.07 Billion
- Q3 2024
A detailed history of Wiley Bros. Aintree Capital, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Wiley Bros. Aintree Capital, LLC holds 2,196 shares of BIIB stock, worth $345,782. This represents 0.01% of its overall portfolio holdings.
Number of Shares
2,196
Previous 1,257
74.7%
Holding current value
$345,782
Previous $291,000
46.05%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding BIIB
# of Institutions
1,038Shares Held
126MCall Options Held
1.13MPut Options Held
1.43M-
Vanguard Group Inc Valley Forge, PA16.7MShares$2.63 Billion0.06% of portfolio
-
Primecap Management CO Pasadena, CA16.3MShares$2.57 Billion2.37% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.29 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.34MShares$1.16 Billion0.06% of portfolio
-
Wellington Management Group LLP Boston, MA5.13MShares$808 Million0.18% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $22.7B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...